Adia Nutrition Inc. Celebrates Approval as Aetna Health Insurance Provider and Anticipates United Healthcare Approval for Adia Med Subsidiary
Adia Nutrition Inc. (OTCQB: ADIA) has achieved a significant milestone with its medical subsidiary, Adia Med, securing approval as an in-network provider for Aetna health insurance effective July 25, 2025. The partnership grants access to 39 million Aetna members and a network of 1.8 million health professionals.
The company is also on track for approval with United Healthcare, the nation's largest health insurer with 15% market share, expected by August 1, 2025. These partnerships will enable broader access to Adia Med's regenerative therapies, including Autologous Hematopoietic Stem Cell Transplantation (AHSCT), Therapeutic Plasma Exchange (TPE), and Medical Nutrition Therapy (MNT).
Adia Nutrition Inc. (OTCQB: ADIA) ha raggiunto un traguardo importante con la sua controllata medica, Adia Med, ottenendo l'approvazione come fornitore in-network per Aetna health insurance a partire dal 25 luglio 2025. Questa collaborazione permette l'accesso a 39 milioni di membri Aetna e a una rete di 1,8 milioni di professionisti sanitari.
L'azienda è inoltre in fase avanzata per ottenere l'approvazione da parte di United Healthcare, il più grande assicuratore sanitario nazionale con una quota di mercato del 15%, prevista entro il 1° agosto 2025. Queste partnership consentiranno un accesso più ampio alle terapie rigenerative di Adia Med, tra cui il Trapianto Autologo di Cellule Staminali Ematopoietiche (AHSCT), lo Scambio Terapeutico di Plasma (TPE) e la Terapia Nutrizionale Medica (MNT).
Adia Nutrition Inc. (OTCQB: ADIA) ha alcanzado un hito importante con su subsidiaria médica, Adia Med, al obtener la aprobación como proveedor dentro de la red para Aetna health insurance a partir del 25 de julio de 2025. Esta alianza otorga acceso a 39 millones de miembros de Aetna y a una red de 1.8 millones de profesionales de la salud.
La compañía también está en camino de obtener la aprobación con United Healthcare, el mayor asegurador de salud del país con una cuota de mercado del 15%, esperada para el 1 de agosto de 2025. Estas asociaciones permitirán un acceso más amplio a las terapias regenerativas de Adia Med, incluyendo el Trasplante Autólogo de Células Madre Hematopoyéticas (AHSCT), el Intercambio Terapéutico de Plasma (TPE) y la Terapia de Nutrición Médica (MNT).
Adia Nutrition Inc. (OTCQB: ADIA)는 의료 자회사 Adia Med가 2025년 7월 25일부터 Aetna 건강 보험의 네트워크 내 제공자로 승인받는 중요한 성과를 이루었습니다. 이번 제휴를 통해 3,900만 명의 Aetna 회원과 180만 명의 의료 전문가 네트워크에 접근할 수 있게 되었습니다.
또한 회사는 2025년 8월 1일까지 미국 최대 건강 보험사인 United Healthcare의 승인도 받을 예정입니다. 이 파트너십들은 자가 조혈모세포 이식(AHSCT), 치료용 혈장 교환(TPE), 의료 영양 치료(MNT) 등 Adia Med의 재생 치료법에 대한 접근성을 확대할 것입니다.
Adia Nutrition Inc. (OTCQB : ADIA) a franchi une étape importante avec sa filiale médicale, Adia Med, qui a obtenu l'approbation en tant que prestataire au sein du réseau de Aetna health insurance à compter du 25 juillet 2025. Ce partenariat donne accès à 39 millions de membres Aetna ainsi qu'à un réseau de 1,8 million de professionnels de santé.
L'entreprise est également en bonne voie pour obtenir l'approbation de United Healthcare, le plus grand assureur santé du pays avec une part de marché de 15 %, attendue pour le 1er août 2025. Ces partenariats permettront un accès élargi aux thérapies régénératives d'Adia Med, incluant la transplantation autologue de cellules souches hématopoïétiques (AHSCT), l'échange thérapeutique de plasma (TPE) et la thérapie nutritionnelle médicale (MNT).
Adia Nutrition Inc. (OTCQB: ADIA) hat mit seiner medizinischen Tochtergesellschaft Adia Med einen bedeutenden Meilenstein erreicht, indem sie ab dem 25. Juli 2025 als Anbieter im Netzwerk von Aetna Health Insurance zugelassen wurde. Die Partnerschaft ermöglicht den Zugang zu 39 Millionen Aetna-Mitgliedern und einem Netzwerk von 1,8 Millionen Gesundheitsfachkräften.
Das Unternehmen steht außerdem kurz vor der Zulassung bei United Healthcare, dem größten Krankenversicherer des Landes mit einem Marktanteil von 15 %, die bis zum 1. August 2025 erwartet wird. Diese Partnerschaften werden einen breiteren Zugang zu den regenerativen Therapien von Adia Med ermöglichen, darunter die Autologe Hämatopoetische Stammzelltransplantation (AHSCT), den Therapeutischen Plasmatransfer (TPE) und die Medizinische Ernährungstherapie (MNT).
- Secured approval as in-network provider for Aetna, accessing 39 million members
- Expected approval with United Healthcare (largest US health insurer) by August 1, 2025
- Access to significant insurance reimbursement pathways in the $15.1B global stem cell market
- Integration with extensive network of 1.8M health professionals and 6,200+ hospitals
- None.
Winter Park, Florida--(Newsfile Corp. - July 28, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized wellness solutions, is thrilled to announce that its medical subsidiary, Adia Med, has been approved as an in-network provider for Aetna health insurance, effective Friday, July 25, 2025. Additionally, Adia Med remains on track for approval as a provider with United Healthcare by this Friday, August 1, 2025, marking significant milestones in expanding access to its cutting-edge regenerative therapies and nutritional services.
Aetna Health
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/260295_aetna_health.jpg
This approval with Aetna allows Adia Med to serve approximately 39 million members across the United States, tapping into Aetna's extensive network of 1.8 million health professionals, including 828,000 primary care providers and specialists, and over 6,200 hospitals. Aetna's health plans, with Affordable Care Act (ACA) marketplace plans averaging
Financial Impact of Insurance Partnerships Aetna processes claims for its 39 million members, with annual medical expenditures estimated in the tens of billions of dollars, covering hospitalization, surgical, medical, vision, and prescription drug expenses. United Healthcare similarly manages billions in annual medical payouts, supporting a wide range of services from primary care to specialized treatments. These partnerships position Adia Nutrition and its Adia Med subsidiary to access significant reimbursement pathways, enhancing affordability and reach for its regenerative medicine and nutritional services.
"We are overjoyed to join Aetna's provider network and are eagerly awaiting our approval with United Healthcare," said Larry Powalisz, CEO of Adia Nutrition Inc. "These partnerships validate the clinical excellence of Adia Med's regenerative therapies and nutritional programs, enabling us to deliver transformative care to millions while driving scalable growth in the
For questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260295
FAQ
When did Adia Nutrition (ADIA) receive approval as an Aetna healthcare provider?
What services will Adia Med offer through Aetna insurance coverage?
How many members will Adia Med have access to through the Aetna partnership?
When is Adia Med expected to receive United Healthcare approval?
What is the size of United Healthcare's market share in health insurance?
